Show simple item record

AuthorSamaha, Ali A.
AuthorMouawia, Hussein
AuthorFawaz, Mirna
AuthorHassan, Hamad
AuthorSalami, Ali
AuthorBazzal, Ali A.
AuthorSaab, Hamid B.
AuthorAl-Wakeel, Mohamed
AuthorAlsaabi, Ahmad
AuthorChouman, Mohamad
AuthorMoussawi, Mahmoud A.
AuthorAyoub, Hassan
AuthorRaad, Ali
AuthorHajjeh, Ola
AuthorEid, Ali H.
AuthorRaad, Houssam
Available date2023-09-25T10:26:16Z
Publication Date2021
Publication NameViruses
ResourceScopus
URIhttp://dx.doi.org/10.3390/v13060989
URIhttp://hdl.handle.net/10576/47953
AbstractObjective: This study was designed to determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was conducted in 100 asymptomatic Lebanese subjects that have tested positive for SARS-CoV2. Fifty patients received standard preventive treatment, mainly supplements, and the experimental group received a single dose (according to body weight) of ivermectin, in addition to the same supplements the control group received. Results: There was no significant difference (p = 0.06) between Ct-values of the two groups before the regimen was started (day zero), indicating that subjects in both groups had similar viral loads. At 72 h after the regimen started, the increase in Ct-values was dramatically higher in the ivermectin than in the control group. In the ivermectin group, Ct increased from 15.13 ± 2.07 (day zero) to 30.14 ± 6.22 (day three; mean ± SD), compared to the control group, where the Ct values increased only from 14.20 ± 2.48 (day zero) to 18.96 ± 3.26 (day three; mean ± SD). Moreover, more subjects in the control group developed clinical symptoms. Three individuals (6%) required hospitalization, compared to the ivermectin group (0%). Conclusion: Ivermectin appears to be efficacious in providing clinical benefits in a randomized treatment of asymptomatic SARS-CoV-2-positive subjects, effectively resulting in fewer symptoms, lower viral load and reduced hospital admissions. However, larger-scale trials are warranted for this conclusion to be further cemented.
Languageen
PublisherMDPI
SubjectClinical trial
COVID-19
Ivermectin
Lebanon
Pandemic
SARS-CoV-2
Therapy
TitleEffects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic sars-cov-2 infected subjects: A pilot clinical trial in lebanon
TypeArticle
Issue Number6
Volume Number13
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record